

Bart de Keizer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5396980/publications.pdf>

Version: 2024-02-01

140
papers

3,560
citations

101384

36
h-index

174990

52
g-index

145
all docs

145
docs citations

145
times ranked

4249
citing authors

#	ARTICLE	IF	CITATIONS
1	CXCR4 expression in glioblastoma tissue and the potential for PET imaging and treatment with [68Ga]Ga-Pentixafor / [177Lu]Lu-Pentixather. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 481-491.	3.3	17
2	Feasibility of sentinel node navigated surgery in high-risk T1b esophageal adenocarcinoma patients using a hybrid tracer of technetium-99m and indocyanine green. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2022, 36, 2671-2679.	1.3	11
3	Intraarterial Administration Boosts ¹⁷⁷ Lu-HA-DOTATATE Accumulation in Salvage Meningioma Patients. <i>Journal of Nuclear Medicine</i> , 2022, 63, 406-409.	2.8	13
4	Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 71-78.	2.0	19
5	¹⁸ F-FDG PET Improves Baseline Clinical Predictors of Response in Diffuse Large B-Cell Lymphoma: The HOVON-84 Study. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1001-1007.	2.8	12
6	Increased vascular inflammation on PET/CT in psoriasis and the effects of biologic treatment: systematic review and meta-analyses. <i>Clinical and Translational Imaging</i> , 2022, 10, 225-235.	1.1	2
7	Retrospective analysis of PSMA PET/CT thyroid incidental uptake in adults: incidence, diagnosis, and treatment/outcome in a tertiary cancer referral center and University Medical Center. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, , 1.	3.3	6
8	Value of Targeted Biopsies and Combined PSMA PET/CT and mp-MRI Imaging in Locally Recurrent Prostate Cancer after Primary Radiotherapy. <i>Cancers</i> , 2022, 14, 781.	1.7	8
9	Quantitative classification and radiomics of [18F]FDG-PET/CT in indeterminate thyroid nodules. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 2174-2188.	3.3	19
10	Detection of sentinel lymph nodes by tilmanocept in oral squamous cell carcinoma. <i>Clinical and Experimental Metastasis</i> , 2022, 39, 417-419.	1.7	1
11	Within-patient comparison between [68Ga]Ga-tilmanocept PET/CT lymphoscintigraphy and [99mTc]Tc-tilmanocept lymphoscintigraphy for sentinel lymph node detection in oral cancer: a pilot study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 2023-2036.	3.3	2
12	FDG PET/CT in differentiated thyroid cancer patients with low thyroglobulin levels. <i>European Journal of Endocrinology</i> , 2022, 187, 101-110.	1.9	4
13	To give or not to give? A critical appraisal of a clinical trial on radioiodine treatment. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, , .	3.3	7
14	Baseline Imaging Derived Predictive Factors of Response Following [177Lu]Lu-PSMA-617 Therapy in Salvage Metastatic Castration-Resistant Prostate Cancer: A Lesion- and Patient-Based Analysis. <i>Biomedicines</i> , 2022, 10, 1575.	1.4	10
15	[68Ga]Ga-tilmanocept PET/CT lymphoscintigraphy: a novel technique for sentinel lymph node imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 963-965.	3.3	15
16	The tubarial salivary glands: A potential new organ at risk for radiotherapy. <i>Radiotherapy and Oncology</i> , 2021, 154, 292-298.	0.3	77
17	Use of an anti-reflux catheter to improve tumor targeting for holmium-166 radioembolization—a prospective, within-patient randomized study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1658-1668.	3.3	13
18	[68Ga]Ga-tilmanocept PET/CT lymphoscintigraphy for sentinel lymph node detection in early-stage oral cavity carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1246-1247.	3.3	3

#	ARTICLE	IF	CITATIONS
19	The tubarial glands paper: A starting point. A reply to comments. <i>Radiotherapy and Oncology</i> , 2021, 154, 308-311.	0.3	10
20	Whole-body MRI versus an FDG-PET/CT-based reference standard for staging of paediatric Hodgkin lymphoma: a prospective multicentre study. <i>European Radiology</i> , 2021, 31, 1494-1504.	2.3	17
21	Sentinel lymph node detection in oral cancer: a within-patient comparison between [^{99m} Tc]Tc-tilmanocept and [^{99m} Tc]Tc-nanocolloid. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 851-858.	3.3	28
22	The Added Value of [¹⁸ F]FDG PET/CT in the Management of Invasive Fungal Infections. <i>Diagnostics</i> , 2021, 11, 137.	1.3	15
23	The prognostic impact of micrometastases and isolated tumor cells in early oral squamous cell carcinoma. <i>European Archives of Oto-Rhino-Laryngology</i> , 2021, 278, 5105-5106.	0.8	3
24	Comparison of different diagnostic approaches in the management of the clinically negative neck in early oral cancer patients. <i>Cancer</i> , 2021, 127, 1959-1962.	2.0	0
25	Current Status and Future Direction of Hepatic Radioembolisation. <i>Clinical Oncology</i> , 2021, 33, 106-116.	0.6	16
26	Doseâ€“Response and Doseâ€“Toxicity Relationships for Glass ⁹⁰ Y Radioembolization in Patients with Liver Metastases from Colorectal Cancer. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1616-1623.	2.8	36
27	Nuclear Medicine Imaging in Neuroblastoma: Current Status and New Developments. <i>Journal of Personalized Medicine</i> , 2021, 11, 270.	1.1	31
28	Contralateral Regional Recurrence in Lateralized or Paramedian Early-Stage Oral Cancer Undergoing Sentinel Lymph Node Biopsyâ€“Comparison to a Historic Elective Neck Dissection Cohort. <i>Frontiers in Oncology</i> , 2021, 11, 644306.	1.3	12
29	Whole-body MRI versus an [¹⁸ F]FDG-PET/CT-based reference standard for early response assessment and restaging of paediatric Hodgkinâ€™s lymphoma: a prospective multicentre study. <i>European Radiology</i> , 2021, 31, 8925-8936.	2.3	10
30	Competition (â€“Stealâ€“™ Phenomenon) between [⁶⁸ Ga]Ga-PSMA-11 Uptake in Prostate Tumor Tissue Versus Healthy Tissue. <i>Pharmaceutics</i> , 2021, 13, 699.	2.0	2
31	European guideline for imaging in paediatric and adolescent rhabdomyosarcoma â€“ joint statement by the European Paediatric Soft Tissue Sarcoma Study Group, the Cooperative Weichteilsarkom Studiengruppe and the Oncology Task Force of the European Society of Paediatric Radiology. <i>Pediatric Radiology</i> , 2021, 51, 1940-1951.	1.1	27
32	Diagnostic accuracy of [^{99m} Tc]Tcâ€“tilmanocept compared to [^{99m} Tc]Tcâ€“nanocolloid for sentinel lymph node identification in earlyâ€“stage oral cancer. <i>Clinical Otolaryngology</i> , 2021, 46, 1383-1388.	0.6	6
33	Aberrant patterns of PET response during treatment for DLBCL patients with MYC gene rearrangements. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, , 1.	3.3	4
34	Evaluation of a streamlined sentinel lymph-node imaging protocol in early-stage oral cancer. <i>Annals of Nuclear Medicine</i> , 2021, 35, 1353-1360.	1.2	0
35	What is the role of sentinel lymph node biopsy in the management of oral cancer in 2020?. <i>European Archives of Oto-Rhino-Laryngology</i> , 2021, 278, 3181-3191.	0.8	27
36	A Rapid and Safe Infusion Protocol for ¹⁷⁷ Lu Peptide Receptor Radionuclide Therapy. <i>Journal of Nuclear Medicine</i> , 2021, 62, 816-822.	2.8	4

#	ARTICLE	IF	CITATIONS
37	Fluorine-18-fluorodeoxyglucose (FDG) positron emission tomography (PET) computed tomography (CT) for the detection of bone, lung, and lymph node metastases in rhabdomyosarcoma. The Cochrane Library, 2021, 2021, CD012325.	1.5	7
38	First experiences with 177Lu-PSMA-617 therapy for recurrent or metastatic salivary gland cancer. EJNMMI Research, 2021, 11, 126.	1.1	15
39	Neuroblastoma stage 4S: Tumor regression rate and risk factors of progressive disease. Pediatric Blood and Cancer, 2020, 67, e28061.	0.8	21
40	Neuroblastoma between 1990 and 2014 in the Netherlands: Increased incidence and improved survival of high-risk neuroblastoma. European Journal of Cancer, 2020, 124, 47-55.	1.3	55
41	Zirconium-89 labelled rituximab PET-CT imaging of Graves' orbitopathy. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 738-739.	3.3	3
42	Elective Neck Dissection or Sentinel Lymph Node Biopsy in Early Stage Oral Cavity Cancer Patients: The Dutch Experience. Cancers, 2020, 12, 1783.	1.7	50
43	PSMA PET/CT Identifies Inpatient Variation in Salivary Gland Toxicity From Iodine-131 Therapy. Molecular Imaging, 2020, 19, 153601212093499.	0.7	6
44	Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84). Journal of Clinical Oncology, 2020, 38, 3377-3387.	0.8	46
45	New Developments in Imaging for Sentinel Lymph Node Biopsy in Early-Stage Oral Cavity Squamous Cell Carcinoma. Cancers, 2020, 12, 3055.	1.7	26
46	Lutetium-177-PSMA therapy for prostate cancer patients – a brief overview of the literature. Tijdschrift Voor Urologie, 2020, 10, 141-146.	0.1	8
47	Prostate-specific membrane antigen (PSMA) expression in adenoid cystic carcinoma of the head and neck. BMC Cancer, 2020, 20, 519.	1.1	25
48	Sa1235 FEASIBILITY OF SENTINEL NODE NAVIGATION SURGERY IN PATIENTS WITH HIGH-RISK SUBMUCOSAL (T1B) ESOPHAGEAL ADENOCARCINOMA USING A HYBRID TRACER OF TECHNETIUM-99M AND INDOCYANINE GREEN. Gastrointestinal Endoscopy, 2020, 91, AB123-AB124.	0.5	0
49	High CXCR4 expression in adenoid cystic carcinoma of the head and neck is associated with increased risk of locoregional recurrence. Journal of Clinical Pathology, 2020, 73, 476-482.	1.0	6
50	Prospective Validation of Gallium-68 Prostate Specific Membrane Antigen-Positron Emission Tomography/Computerized Tomography for Primary Staging of Prostate Cancer. Journal of Urology, 2020, 203, 537-545.	0.2	79
51	68Ga-PSMA PET/CT in radioactive iodine-refractory differentiated thyroid cancer and first treatment results with 177Lu-PSMA-617. EJNMMI Research, 2020, 10, 18.	1.1	46
52	New national recommendations for the treatment of pediatric differentiated thyroid carcinoma in the Netherlands. European Journal of Endocrinology, 2020, 183, P11-P18.	1.9	23
53	FEASIBILITY OF SENTINEL NODE NAVIGATED SURGERY IN PATIENTS WITH HIGH-RISK SUBMUCOSAL (T1B) ESOPHAGEAL ADENOCARCINOMA USING A HYBRID TRACER OF TECHNETIUM-99M AND INDOCYANINE GREEN. Endoscopy, 2020, 52, .	1.0	0
54	OC-020 Sentinel lymph node biopsy for early stage oral cancer; experience of 3 Dutch Head and Neck centers. Radiotherapy and Oncology, 2019, 132, 12-13.	0.3	0

#	ARTICLE	IF	CITATIONS
55	OC-022 Unexpected drainage patterns and high accuracy of SLNB in OSCC after previous neck treatment. <i>Radiotherapy and Oncology</i> , 2019, 132, 13-14.	0.3	0
56	Zirconium-89-labelled rituximab PET-CT in orbital inflammatory disease. <i>EJNMMI Research</i> , 2019, 9, 69.	1.1	19
57	Prostate-specific membrane antigen expression in hepatocellular carcinoma: potential use for prognosis and diagnostic imaging. <i>Oncotarget</i> , 2019, 10, 4149-4160.	0.8	31
58	New Developments in Sentinel Lymph Node Biopsy Procedure in Localized Oral Cancer. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2019, 145, 741.	1.2	3
59	Depth of invasion in patients with early stage oral cancer staged by sentinel node biopsy. <i>Head and Neck</i> , 2019, 41, 2100-2106.	0.9	30
60	High rate of unexpected lymphatic drainage patterns and a high accuracy of the sentinel lymph node biopsy in oral cancer after previous neck treatment. <i>Oral Oncology</i> , 2019, 94, 68-72.	0.8	23
61	S1599 RITUXIMAB MAINTENANCE FOR PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA IN FIRST COMPLETE REMISSION: RESULTS FROM A RANDOMIZED HOVON-NORDIC LYMPHOMA GROUP PHASE III STUDY. <i>HemaSphere</i> , 2019, 3, 736.	1.2	0
62	RITUXIMAB MAINTENANCE FOR PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA IN FIRST COMPLETE REMISSION: RESULTS FROM A RANDOMIZED HOVON-NORDIC LYMPHOMA GROUP PHASE III STUDY. <i>Hematological Oncology</i> , 2019, 37, 79-80.	0.8	1
63	Fast-track Radioiodine Ablation Therapy After Thyroidectomy Reduces Sick Leave in Patients With Differentiated Thyroid Cancer (FASTHYNA Trial). <i>Clinical Nuclear Medicine</i> , 2019, 44, 272-275.	0.7	11
64	Fused high b-value diffusion weighted and T2-weighted MR images in staging of pediatric Hodgkin's lymphoma: A pilot study. <i>European Journal of Radiology</i> , 2019, 121, 108737.	1.2	4
65	First Experience With 177Lu-PSMA-617 Therapy for Advanced Prostate Cancer in the Netherlands. <i>Clinical Nuclear Medicine</i> , 2019, 44, 446-451.	0.7	22
66	Healthy Tissue Uptake of 68Ga-Prostate-Specific Membrane Antigen, 18F-DCFPyL, 18F-Fluoromethylcholine, and 18F-Dihydrotestosterone. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1111-1117.	2.8	23
67	Rituximab maintenance for patients with diffuse large B-cell lymphoma in first complete remission: Results from a randomized HOVON-Nordic Lymphoma Group phase III study. <i>Journal of Clinical Oncology</i> , 2019, 37, 7507-7507.	0.8	3
68	Physiologic distribution of PSMA-ligand in salivary glands and seromucous glands of the head and neck on PET/CT. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2018, 125, 478-486.	0.2	58
69	PET Molecular Targets and Near-Infrared Fluorescence Imaging of Atherosclerosis. <i>Current Cardiology Reports</i> , 2018, 20, 11.	1.3	12
70	Impact of external cooling with icepacks on 68Ga-PSMA uptake in salivary glands. <i>EJNMMI Research</i> , 2018, 8, 56.	1.1	54
71	Prediction of ultrasound guided fine needle aspiration cytology results by FDG PET-CT for lymph node metastases in head and neck squamous cell carcinoma patients. <i>Acta Oncologica</i> , 2018, 57, 1687-1692.	0.8	11
72	Detection of distant interval metastases after neoadjuvant therapy for esophageal cancer with 18F-FDG PET/(CT): a systematic review and meta-analysis. <i>Ecological Management and Restoration</i> , 2018, 31, .	0.2	31

#	ARTICLE	IF	CITATIONS
73	The theranostic target prostate-specific membrane antigen is expressed in medullary thyroid cancer. <i>Human Pathology</i> , 2018, 81, 245-254.	1.1	14
74	Interobserver Agreement of Interim and End-of-Treatment ¹⁸ F-FDG PET/CT in Diffuse Large B-Cell Lymphoma: Impact on Clinical Practice and Trials. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1831-1836.	2.8	23
75	Is there a place for FDG-PET-CT in early oral cancer patients?. <i>Oral Oncology</i> , 2018, 84, 123-124.	0.8	2
76	SSTR2A expression in medullary thyroid carcinoma is correlated with longer survival. <i>Endocrine</i> , 2018, 62, 639-647.	1.1	9
77	¹⁸ F Fluorocholine PET/MR Imaging in Patients with Primary Hyperparathyroidism and Inconclusive Conventional Imaging: A Prospective Pilot Study. <i>Radiology</i> , 2017, 284, 460-467.	3.6	73
78	A phantom study: Should ¹²⁴ Iâ€mIBG PET/CT replace ¹²³ Iâ€mIBG SPECT/CT?. <i>Medical Physics</i> , 2017, 44, 1624-1631.	1.6	19
79	Gastrointestinal stromal tumour detection with somatostatin receptor imaging, ⁶⁸ Ga-HA-DOTATATE PETâ€CT. <i>Lancet Oncology</i> , The, 2017, 18, e185.	5.1	4
80	Diagnostic performance of computed tomography for parathyroid adenoma localization; a systematic review and meta-analysis. <i>European Journal of Radiology</i> , 2017, 88, 117-128.	1.2	56
81	Accuracy of bone mineral density quantification using dual-layer spectral detector CT: a phantom study. <i>European Radiology</i> , 2017, 27, 4351-4359.	2.3	60
82	Follow-up of patients with thyroglobulin-antibodies: Rising Tg-Ab trend is a risk factor for recurrence of differentiated thyroid cancer. <i>Endocrine Research</i> , 2017, 42, 302-310.	0.6	17
83	Prostate-specific membrane antigen PET imaging and immunohistochemistry in adenoid cystic carcinoma: a preliminary analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1614-1621.	3.3	41
84	Reply: THYROPET Study: Is It Biology or Technology That Is the Issue?. <i>Journal of Nuclear Medicine</i> , 2017, 58, 354.2-355.	2.8	1
85	OC-007: Sentinel node biopsy for early stage oral cancer; experience of 2 Dutch head and neck centers. <i>Radiotherapy and Oncology</i> , 2017, 122, 7.	0.3	0
86	FDGâ€PET as a Biomarker of Response in DLBCL: the HOVON 84 Study Experience. <i>Hematological Oncology</i> , 2017, 35, 40-41.	0.8	0
87	⁶⁸ Ga-PSMA PET-CT Imaging of Metastatic Adenoid Cystic Carcinoma. <i>Nuclear Medicine and Molecular Imaging</i> , 2017, 51, 360-361.	0.6	17
88	Response assessment after induction chemotherapy for head and neck squamous cell carcinoma: From physical examination to modern imaging techniques and beyond. <i>Head and Neck</i> , 2017, 39, 2329-2349.	0.9	26
89	Urothelial carcinoma in an orthotopic neobladder: an unusual pattern of recurrence and metastasis. <i>BMJ Case Reports</i> , 2017, 2017, bcr-2017-221052.	0.2	5
90	Detection of Synchronous Parathyroid Adenoma and Breast Cancer with ¹⁸ F-Fluorocholine PET-CT. <i>Nuclear Medicine and Molecular Imaging</i> , 2016, 50, 180-182.	0.6	2

#	ARTICLE	IF	CITATIONS
91	Letter to the Editor Regarding the Article ¹²⁴ I PET/CT in Patients with Differentiated Thyroid Cancer: Clinical and Quantitative Image Analysis. <i>Thyroid</i> , 2016, 26, 1141-1142.	2.4	2
92	Use of PET tracers for parathyroid localization: a systematic review and meta-analysis. <i>Langenbeck's Archives of Surgery</i> , 2016, 401, 925-935.	0.8	85
93	Calibration of PET/CT scanners for multicenter studies on differentiated thyroid cancer with ¹²⁴ I. <i>EJNMMI Research</i> , 2016, 6, 39.	1.1	6
94	Fluorine-18 fluorocholine PET-CT localizes hyperparathyroidism in patients with inconclusive conventional imaging. <i>Nuclear Medicine Communications</i> , 2016, 37, 1246-1252.	0.5	64
95	⁸⁹ Zr-rituximab PET/CT to detect neurolymphomatosis. <i>American Journal of Hematology</i> , 2016, 91, 649-650.	2.0	3
96	Thyroid Ultrasound-Guided Fine-Needle Aspiration: The Positive Influence of On-Site Adequacy Assessment and Number of Needle Passes on Diagnostic Cytology Rate. <i>Acta Cytologica</i> , 2016, 60, 39-45.	0.7	46
97	¹²⁴ I PET/CT to Predict the Outcome of Blind ¹³¹ I Treatment in Patients with Biochemical Recurrence of Differentiated Thyroid Cancer: Results of a Multicenter Diagnostic Cohort Study (THYROPET). <i>Journal of Nuclear Medicine</i> , 2016, 57, 701-707.	2.8	39
98	Quantitative Comparison of ¹²⁴ I PET/CT and ¹³¹ I SPECT/CT Detectability. <i>Journal of Nuclear Medicine</i> , 2016, 57, 103-108.	2.8	26
99	Use of C-Arm Cone Beam CT During Hepatic Radioembolization: Protocol Optimization for Extrahepatic Shunting and Parenchymal Enhancement. <i>CardioVascular and Interventional Radiology</i> , 2016, 39, 64-73.	0.9	20
100	Accuracy of whole-body MRI in the assessment of splenic involvement in lymphoma. <i>Acta Radiologica</i> , 2016, 57, 142-151.	0.5	18
101	Randomized phase III study on the effect of early intensification of rituximab in combination with 2-weekly CHOP chemotherapy followed by rituximab or no maintenance in patients with diffuse large B-cell lymphoma: Results from a HOVON-Nordic Lymphoma Group study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7504-7504.	0.8	17
102	¹⁸ F-Fluorocholine PET-CT enables minimal invasive parathyroidectomy in patients with negative sestamibi SPECT-CT and ultrasound: A case report. <i>International Journal of Surgery Case Reports</i> , 2015, 13, 73-75.	0.2	8
103	New Insights in Resistance to Interchange. <i>Transportation Research Procedia</i> , 2015, 8, 72-79.	0.8	7
104	Whole-body MRI-DWI for assessment of residual disease after completion of therapy in lymphoma: A prospective multicenter study. <i>Journal of Magnetic Resonance Imaging</i> , 2015, 42, 1646-1655.	1.9	39
105	The use of ¹⁸ F-FDG PET to differentiate progressive disease from treatment induced necrosis in high grade glioma. <i>Journal of Neuro-Oncology</i> , 2015, 125, 167-175.	1.4	27
106	Qualitative elastography can replace thyroid nodule fine-needle aspiration in patients with soft thyroid nodules. A systematic review and meta-analysis. <i>European Journal of Radiology</i> , 2015, 84, 652-661.	1.2	57
107	The role of qualitative elastography in thyroid nodule evaluation: exploring its target populations. <i>Endocrine</i> , 2015, 50, 265-267.	1.1	3
108	Enabling minimal invasive parathyroidectomy for patients with primary hyperparathyroidism using Tc- ^{99m} -sestamibi SPECT-CT, ultrasound and first results of ¹⁸ F-fluorocholine PET-CT. <i>European Journal of Radiology</i> , 2015, 84, 1745-1751.	1.2	68

#	ARTICLE	IF	CITATIONS
109	Modest utility of quantitative measures in 18 F-fluorodeoxyglucose positron emission tomography scanning for the diagnosis of aortic prosthetic graft infection. <i>Journal of Vascular Surgery</i> , 2015, 61, 965-971.	0.6	44
110	Opportunistic screening for osteoporosis on routine computed tomography? An external validation study. <i>European Radiology</i> , 2015, 25, 2074-2079.	2.3	100
111	Differential FDG-PET Uptake Patterns in Uninfected and Infected Central Prosthetic Vascular Grafts. <i>European Journal of Vascular and Endovascular Surgery</i> , 2015, 50, 376-383.	0.8	48
112	Systematic review and meta-analysis on the diagnostic performance of FDG-PET/CT in detecting bone marrow involvement in newly diagnosed Hodgkin lymphoma: is bone marrow biopsy still necessary?. <i>Annals of Oncology</i> , 2014, 25, 921-927.	0.6	113
113	Whole-body MRI for initial staging of paediatric lymphoma: prospective comparison to an FDG-PET/CT-based reference standard. <i>European Radiology</i> , 2014, 24, 1153-1165.	2.3	96
114	FDG PET/CT for the detection of bone marrow involvement in diffuse large B-cell lymphoma: systematic review and meta-analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 565-574.	3.3	135
115	Identifying Aberrant Hepatic Arteries Prior to Intra-arterial Radioembolization. <i>CardioVascular and Interventional Radiology</i> , 2014, 37, 1482-1493.	0.9	18
116	Recurrent differentiated thyroid cancer: towards personalized treatment based on evaluation of tumor characteristics with PET (THYROPET Study): study protocol of a multicenter observational cohort study. <i>BMC Cancer</i> , 2014, 14, 405.	1.1	21
117	High Negative Predictive Value (NPV) Of Undetectable TSH Stimulated Tg For Disease Recurrence In Both Low And High Risk Differentiated Thyroid Cancer. <i>Journal of Thyroid Disorders & Therapy</i> , 2014, 03, .	0.1	0
118	Relationship between pretreatment FDG-PET and diffusion-weighted MRI biomarkers in diffuse large B-cell lymphoma. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 4, 231-8.	1.0	10
119	Potential Clinical Applications of PET/Magnetic Resonance Imaging. <i>PET Clinics</i> , 2013, 8, 367-384.	1.5	3
120	Whole-body MRI for the detection of bone marrow involvement in lymphoma: prospective study in 116 patients and comparison with FDG-PET. <i>European Radiology</i> , 2013, 23, 2271-2278.	2.3	44
121	High FDG Uptake in the Right Ventricular Myocardium of a Pulmonary Hypertension Patient. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1724.	1.2	10
122	False-positive PET scan after bone marrow biopsy. <i>British Journal of Haematology</i> , 2013, 161, 753-753.	1.2	3
123	High Failure Rates After ¹³¹ I Therapy in Graves Hyperthyroidism Patients With Large Thyroid Volumes, High Iodine Uptake, and High Iodine Turnover. <i>Clinical Nuclear Medicine</i> , 2013, 38, 401-406.	0.7	48
124	Quantitative Comparison of PET and Bremsstrahlung SPECT for Imaging the In Vivo Yttrium-90 Microsphere Distribution after Liver Radioembolization. <i>PLoS ONE</i> , 2013, 8, e55742.	1.1	162
125	Reply: Utility of Diagnostic Whole-Body Iodine Scanning in High-Risk Differentiated Thyroid Carcinoma. <i>Journal of Nuclear Medicine</i> , 2012, 53, 662-663.	2.8	0
126	Breast cancer sentinel node scintigraphy. <i>Nuclear Medicine Communications</i> , 2012, 33, 1138-1143.	0.5	2

#	ARTICLE	IF	CITATIONS
127	Not the Number but the Location of Lymph Nodes Matters for Recurrence Rate and Disease-Free Survival in Patients with Differentiated Thyroid Cancer. <i>World Journal of Surgery</i> , 2012, 36, 1262-1267.	0.8	78
128	The Role of Routine Diagnostic Radioiodine Whole-Body Scintigraphy in Patients with High-Risk Differentiated Thyroid Cancer. <i>Journal of Nuclear Medicine</i> , 2011, 52, 56-59.	2.8	48
129	Value of diagnostic radioiodine scintigraphy and thyroglobulin measurements after rhTSH injection. <i>Nuklearmedizin - NuclearMedicine</i> , 2009, 48, 26-9.	0.3	2
130	Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 749-755.	3.3	104
131	I-131 Accumulation in a Benign Cystic Mesothelioma in a Patient with Follicular Thyroid Cancer. <i>Thyroid</i> , 2008, 18, 369-371.	2.4	8
132	Use of Radiopharmaceuticals for Diagnosis, Treatment, and Follow-Up of Differentiated Thyroid Carcinoma. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2007, 7, 399-409.	0.9	7
133	FDG-PET combined with CT considerably alters tumour delineation for radiotherapy for h&n cancer compared to CT only. <i>Radiotherapy and Oncology</i> , 2007, 82, S6.	0.3	0
134	Persistent Disease in Patients with Papillary Thyroid Carcinoma and Lymph Node Metastases After Surgery and Iodine-131 Ablation. <i>World Journal of Surgery</i> , 2007, 31, 2309-2314.	0.8	8
135	Prognostic significance of successful ablation with radioiodine of differentiated thyroid cancer patients. <i>European Journal of Endocrinology</i> , 2005, 152, 33-37.	1.9	93
136	Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer. <i>Journal of Nuclear Medicine</i> , 2004, 45, 1549-54.	2.8	42
137	Tumour dosimetry and response in patients with metastatic differentiated thyroid cancer using recombinant human thyrotropin before radioiodine therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2003, 30, 367-373.	3.3	62
138	Efficacy of high therapeutic doses of iodine-131 in patients with differentiated thyroid cancer and detectable serum thyroglobulin. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2001, 28, 198-202.	2.2	45
139	Fixed dosage of 131I for remnant ablation in patients with differentiated thyroid carcinoma without pre-ablative diagnostic 131I scintigraphy. <i>Nuclear Medicine Communications</i> , 2000, 21, 529-532.	0.5	49
140	Holmium-166 Radioembolization. <i>Digestive Disease Interventions</i> , 0, 05, .	0.3	0